Merck and Immune Design have entered into an agreement under which Merck, through a subsidiary, will acquire Immune Design for approximately $300 million.   “Scientists at Immune Design have established a unique portfolio of approaches to cancer immunization and adjuvant systems designed to enhance the ability of a vaccine to protect against infection, which could meaningfully improve vaccine development,” said Roger Perlmutter, president, Merck Research Laboratories. “This acquisition bui...